Utilico Insights - Jacqueline Broers assesses why Vietnam could be the darling of Asia for investors. Watch the full video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 10,678.00
Bid: 10,688.00
Ask: 10,690.00
Change: -64.00 (-0.60%)
Spread: 2.00 (0.019%)
Open: 10,756.00
High: 10,780.00
Low: 10,674.00
Prev. Close: 10,742.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UPDATE 3-AstraZeneca raises forecasts after seeing off Pfizer

Thu, 31st Jul 2014 10:45

* One-off payments and tax benefit flatter Q2 results

* Investors focused on possible Pfizer return

* Q2 revenue $6.45 billion vs consensus $6.29 billion

* Q2 core EPS $1.30 vs consensus $1.10

* Now assuming generic Nexium in U.S. from Oct. 1 (Adds CEO comments from conference call, further analystcomment)

By Ben Hirschler

LONDON, July 31 (Reuters) - AstraZeneca raised itssales and earnings forecasts for the year on Thursday, showingresilience after seeing off a $118 billion takeover approachfrom rival Pfizer two months ago.

Second-quarter sales and earnings both beat expectations,helped by several one-off factors, including a product-relatedpayment from Pfizer worth $200 million.

Chief Executive Pascal Soriot has fought hard to demonstratethat AstraZeneca has a strong independent future and does notneed the kind of mega-merger offered by its bigger U.S. rival, despite the fact some investors favour a deal.

He declined to comment on whether Pfizer might return butsaid he would flag AstraZeneca's progress as a standalone groupat an investor day on Nov. 18 - just before a mandatorysix-month cooling off period ends and Pfizer can renew itsapproach.

Soriot has gained credit for his firm's pipeline ofpromising new cancer drugs, while the respiratory business hasbeen boosted by strong demand for Symbicort, which has takenbusiness from GlaxoSmithKline's rival drug Advair.

AstraZeneca moved to boost its lung drug franchise furtheron Wednesday by acquiring rights to Spanish group Almirall's lung treatments in a deal worth up to $2.1 billion.

Sales in the quarter rose 4 percent to $6.45 billion,despite generic competition to some drugs, generating coreearnings - which exclude certain items - up 8 percent at $1.30 ashare.

Industry analysts, on average, had forecast sales in thequarter of $6.29 billion and earnings of $1.10 a share,according to Thomson Reuters data.

"There is clearly visible momentum across our business as wecontinue to execute on our strategy of returning to growth andachieving scientific leadership," Soriot told reporters. "We nowhave one of the most exciting pipelines in the industry."

He also said he hoped to strike partnering deals in thesecond half of 2014 for certain anti-infective and neurosciencedrugs - including an experimental treatment for Alzheimer's -which will help reduce some of the firm's drug developmentcosts.

GENERIC NEXIUM DELAY

Revenue in 2014 is now expected to be in line with 2013 atconstant exchange rates - an increase on the previous forecastof a low to mid single-digit percentage decline - and coreearnings per share are set for a low double-digit declineinstead of a percentage decrease in the teens.

Deutsche Bank analyst Mark Clark said the resultsrepresented a "big beat" but were flattered by one-time itemsand the improved outlook for the year was likely to be taken inits stride by the market.

Shares in the company were little changed at 4,351 pence by1042 GMT.

A raft of patent expiries will pressure sales and profitsuntil at least 2017 but Britain's second-biggest pharmaceuticalsgroup is currently enjoying a partial reprieve, due to thedelayed U.S. launch of a generic form of heartburn pill Nexium.

AstraZeneca now assumes, for planning purposes, that genericversions of prescription Nexium will reach the U.S. market onOct. 1.

India's Ranbaxy Laboratories holds the rights tosell the first generic copy of the popular drug but itscontinuing problems with meeting regulatory standards inmanufacturing have delayed a launch.

AstraZeneca's quarterly results were also boosted by a $200million milestone payment from Pfizer, following the U.S.company's launch of an over-the-counter version of Nexium inMay, and a $80 million payment related to the Japanese launch ofdiabetes drug Forxiga.

The company enjoyed a further $117 million benefit from aninter-governmental agreement on a transfer pricing matter, whichcut the tax rate in the period sharply.

PFIZER RETURN?

Many investors believe Pfizer will be back in late Novemberafter an enforced six-month cooling-off period - assumingAstraZeneca does not invite it back before then - because thelogic of a deal remains strong.

Jefferies analyst Jeffrey Holford said the fact thatAstraZeneca had set an investor day for Nov. 18 implied it was"very unlikely" to invite Pfizer back for talks at the end ofAugust, as it could in theory do under British takeover rules.

Pfizer would slash its tax bill by moving its tax address toBritain, in a process known as inversion. The case for such taxinversions remains compelling, as evidenced by AbbVie's successful pursuit of Shire.

The U.S. company would not be drawn on its plans forAstraZeneca when it reported results two days ago but said itwas still considering big deals. (Editing by Tom Pfeiffer and Greg Mahlich)

More News
27 Mar 2024 12:02

LONDON MARKET MIDDAY: FTSE 100 underperforms ahead of US PCE data

(Alliance News) - Stock prices in London were lower at midday on Wednesday, but trade was more confident in mainland Europe, with focus turning to the release of the US Federal Reserve's preferred inflation gauge on Friday.

Read more
27 Mar 2024 11:56

C4X Discovery seeks AIM delisting but half-year revenue skyrockets

(Alliance News) - C4X Discovery Holdings PLC shares plunged on Wednesday after it said it plans to delist from AIM in London, due to "the recent downturn in the financial markets" hampering its valuation.

Read more
27 Mar 2024 09:19

AstraZeneca treatments become "first and only" to be approved in Japan

(Alliance News) - AstraZeneca PLC announced on Wednesday the approval of two of its treatments for use in Japan.

Read more
27 Mar 2024 09:03

LONDON MARKET OPEN: FTSE 100 slips as unease lingers before US data

(Alliance News) - Stock prices in London edged lower after the open on Wednesday, with some nervy trade ahead of a US inflation reading later in the week.

Read more
27 Mar 2024 08:02

LONDON BRIEFING: Diploma makes buy; Astra wins Japan drug approvals

(Alliance News) - Stocks in London opened in a muted fashion on Wednesday, with some unease lingering in equity markets ahead of a US inflation reading later in the week.

Read more
26 Mar 2024 10:18

China to speed up 'new productive forces', vice president says

BEIJING, March 26 (Reuters) - China will accelerate the development of "new productive forces" and bolster stability and security for the global economy, Vice President Han Zheng told an investment forum in Beijing, as the world's no.2 economy seeks to reassure anxious foreign firms.

Read more
25 Mar 2024 12:09

LONDON MARKET MIDDAY: Stocks make tepid start to new week

(Alliance News) - Stock prices in London were down at midday on Monday, giving back some gains from last week, when equities were boosted by central bank decisions and accompanying statements which investors saw as dovish.

Read more
25 Mar 2024 09:04

LONDON MARKET OPEN: FTSE 100 treads water, FTSE 250 declines

(Alliance News) - The FTSE 100 in London traded flat early Monday, while the pound remained below the USD1.26 mark, as Bank of England Governor Andrew Bailey suggested rate cuts may happen soon.

Read more
25 Mar 2024 08:40

TOP NEWS: AstraZeneca wins US approval for rare nervous system disease

(Alliance News) - AstraZeneca PLC on Monday said its Ultomiris treatment has been approved by the US Food & Drug Administration as the first and only long-acting C5 complement inhibitor to treat neuromyelitis optica spectrum disorder in adults.

Read more
25 Mar 2024 07:59

LONDON BRIEFING: AstraZeneca wins US approval, Kingfisher profit down

(Alliance News) - London's FTSE 100 is set to open lower on Monday, giving back some of last week's progress, when equities were boosted by hope of interest rate cuts.

Read more
25 Mar 2024 07:23

AstraZeneca gets FDA approval for Ultomiris treatment

(Sharecast News) - AstraZeneca has announced that its autoimmune disease treatment Ultomiris has been given the green light by US regulators.

Read more
21 Mar 2024 16:43

AstraZeneca's Tagrisso successful in treating lung cancer

(Alliance News) - AstraZeneca PLC on Thursday reported positive findings following a phase III trial of its lung cancer Tagrisso treatment.

Read more
19 Mar 2024 08:56

TOP NEWS: AstraZeneca to buy Fusion in deal worth over USD2 billion

(Alliance News) - AstraZeneca PLC on Tuesday said it will buy Fusion Pharmaceuticals Inc, a Canada-based clinical-stage biopharmaceutical company developing "next-generation" radioconjugates.

Read more
19 Mar 2024 07:05

AstraZeneca to buy US-listed Fusion Phrama for $2bn

(Sharecast News) - AstraZeneca said it had agreed to buy biopharmaceutical company Fusion Pharmaceuticals for up to $2bn.

Read more
18 Mar 2024 16:09

UK dividends calendar - next 7 days

Tuesday 19 March 
Jarvis Securities PLCdividend payment date
Wednesday 20 March 
Virgin Money UK PLCdividend payment date
Thursday 21 March 
abrdn Asia Focus PLCdividend payment date
abrdn Private Equity Opportunities Trust PLCex-dividend payment date
AIB Group PLCex-dividend payment date
Beazley PLCex-dividend payment date
BlackRock World Mining Trust PLCex-dividend payment date
British American Tobacco PLCex-dividend payment date
Chemring Group PLCex-dividend payment date
CLS Holdings PLCex-dividend payment date
Conduit Holdings Ltdex-dividend payment date
Craneware PLCex-dividend payment date
Crest Nicholson Holdings PLCex-dividend payment date
Diverse Income Trust PLCex-dividend payment date
Fonix Mobile PLCex-dividend payment date
FW Thorpe PLCex-dividend payment date
Glanbia PLCex-dividend payment date
GlobalData PLCex-dividend payment date
Globalworth Real Estate Investments Ltdex-dividend payment date
Goodwin PLCex-dividend payment date
Gore Street Energy Storage Fund PLCex-dividend payment date
Hargreaves Services PLCex-dividend payment date
HgCapital Trust PLCex-dividend payment date
Hikma Pharmaceuticals PLCex-dividend payment date
Jardine Matheson Holdings LDex-dividend payment date
London Finance & Investment Group PLCex-dividend payment date
Maven Income & Growth VCT 3 PLCex-dividend payment date
Maven Income & Growth VCT 5 PLCex-dividend payment date
MTI Wireless Edge Ltdex-dividend payment date
Nichols PLCex-dividend payment date
NWF Group PLCex-dividend payment date
Palace Capital PLCex-dividend payment date
Pearson PLCex-dividend payment date
Pembroke VCT B PLCex-dividend payment date
Primorus Investments PLCex-dividend payment date
Schroders PLCex-dividend payment date
Triple Point Energy Transition PLCex-dividend payment date
Tristel PLCex-dividend payment date
VPC Specialty Lending Investments PLCdividend payment date
Friday 22 March 
easyJet PLCdividend payment date
FRP Advisory Group PLCdividend payment date
Gulf Investment Fund PLCdividend payment date
Henderson Opportunities Trust PLCdividend payment date
Hercules Site Services PLCdividend payment date
Impax Asset Management Group PLCdividend payment date
JLEN Environmental Assets Group Ltddividend payment date
JPMorgan Multi-Asset Growth & Income PLCdividend payment date
Mattioli Woods PLCdividend payment date
Mobeus Income & Growth 2 VCT PLCdividend payment date
Mobeus Income & Growth 4 VCT PLCdividend payment date
Ramsdens Holdings PLCdividend payment date
Riverstone Credit Opportunities Income PLCdividend payment date
Ruffer Investment Co Ltddividend payment date
Samuel Heath & Sons PLCdividend payment date
Troy Income & Growth Trust PLCdividend payment date
Unilever PLCdividend payment date
Monday 25 March 
AstraZeneca PLCdividend payment date
Endeavour Mining PLCdividend payment date
Mountview Estates PLCdividend payment date
Shell PLCdividend payment date
  
Comments and questions to newsroom@alliancenews.com
  
A full 14-day events calendar is provided each day with a subscription to Alliance News UK Professional.
  
Copyright 2024 Alliance News Ltd. All Rights Reserved.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.